At the just-concluded "2022-2023 China Pharmaceutical Industry Most Influential List Press Conference and the 15th China Pharmaceutical Industry Development Forum", the conference not only released a number of industry lists such as China's top 100 pharmaceutical manufacturing industries, China's top 100 pharmaceutical businesses, and China's pharmaceutical industry innovation pioneers, but also Kangyuan Group has also become the "2022-2023 China's most influential list of pharmaceutical industry" by virtue of its outstanding R&D and innovation strength and strong core competitiveness Academician Xiao Wei, Secretary of the Party Committee and Honorary Chairman of the Group, won the "Pioneer of China's Pharmaceutical Independent Innovation" award, Kangji Pharmacy won the "Law-abiding and Honest Enterprise of China's Pharmaceutical Industry" award, Kangyuan Pharmaceutical Business ranked 33rd in the "Top 100 Chinese Pharmaceutical Businesses", and the Group ranked 18th in the "Top 100 Pharmaceutical Manufacturing Enterprises in China" and 6th in the "Pioneer Enterprises of China's Pharmaceutical Independent Innovation".
The reason why Kangyuan Group can become the focus brand on the "2022-2023 Most Influential List of China's Pharmaceutical Industry" is inseparable from ingenuity and continuous empowerment of scientific and technological innovation. Inheriting the sincerity of national medicine for thousands of years, creating a century-old blueprint for evergreening. Since its establishment, Kangyuan Group has always adhered to the core values of "HOPU Yuanzhi and Innovation Striving for the First", actively practiced the great mission of "Revitalizing Sinopharm and Serving the Motherland", and always planned and laid out the whole industrial chain of Chinese medicine under the guidance of the "innovation-driven" development strategy.
Now, Kangyuan Group has not only set up a postdoctoral research workstation, an academician workstation in Jiangsu Province, established a Kangyuan Modern Chinese Medicine Research Institute, and established an innovative drug research and development company in the United States, with independent innovation capabilities and invention patents authorized among the best in the industry. It is worth mentioning that Kangyuan Group has not also established intelligent manufacturing standards for the traditional Chinese medicine industry, has the largest intelligent Chinese herbal medicine extraction production line in China, and has the ability to process 10,000 tons of raw medicinal materials annually, and has been included in the national intelligent manufacturing pilot demonstration project by the Ministry of Industry and Information Technology.
The 2022-2023 press conference of the most influential list in China's pharmaceutical industry returned with a full load, showing the solid industry position of Kangyuan Group. With ingenuity manufacturing and technological innovation, Kangyuan Group provides high-quality medicines for major theaters and patients, and actively empowers the construction of a healthy China.